A tiny biotech with a unique platform is stepping into the global spotlight ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily.
A tiny biotech with a unique platform is stepping into the global spotlight—and it could be one of the most overlooked antiviral opportunities in the market today. NanoViricides, Inc. (NYSE: NNVC) is developing NV-387, a broad-spectrum antiviral drug currently in human trials for COVID-19, with promising preclinical activity against major viral threats including: With the World Health Organization extending the global emergency status of the MPox epidemic, NNVC’s announcement that it is moving forward with Phase II trials for NV-387 in Africa’s deadliest Mpox clade (Clade I) is perfectly timed—and investors are starting to notice. Analysts from Zacks SCR and ProactiveInvestors see the company’s nanomedicine platform as a potential game-changer in the $3B respiratory viral market—and potentially far beyond. What sets NNVC apart? ✅ A first-in-class nanomedicine that traps viruses before they infect cells
✅ Broad-spectrum activity, even against mutating viruses
✅ A differentiated approach that may rival the pharma giants
✅ Platform potential with multiple shots on goal—COVID-19, RSV, measles, Mpox, and more The company’s recent ethics approval in the DRC to begin Phase II human trials for MPox treatment puts NNVC on the front line of a growing global health concern—one with multi-billion-dollar pandemic and bioterror preparedness implications. This isn’t just about treating MPox. This is about building a global antiviral defense system—and NNVC’s technology could play a vital role. With momentum building and a pipeline unlike anything else in the small-cap space, NanoViricides, Inc. (NYSE: NNVC) may be positioning itself for breakout success. 👉 Get the full breakdown on NanoViricides (NYSE: NNVC) and why investors are tuning in now. |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $5,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 08/01/2025. Behind the Markets
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. |
|
Tidak ada komentar:
Posting Komentar